









Atlas Genet Cytogenet Oncol Haematol. 2008;12(1)  27 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology                         
                         OPEN ACCESS JOURNAL AT INIST-CNRS 
ASCL1 (achaete-scute homolog 1 or achaete-scute 
complex homolog 1) 
Jayashree S Ladha, MRS Rao 
Jawaharlal Nehru Centre for Advanced Scientific Research -A Deemed University- Jakkur P.O., Bangalore-
560064, India 
Published in Atlas Database: July 2007 
Online updated version: http://AtlasGeneticsOncology.org/Genes/ASCL1ID713ch12q23.html  
DOI: 10.4267/2042/38469 
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. 




Other names: ASH1; HASH1; MASH1 
Location: 12q23.2 
Note: Renault B et al performed fluorescent in situ 
hybridisation using YAC 896h that contains ASCL1 
and other chromosome 12 specific markers such as 
IGF1, PAH and TRA1 to localise ASCL1. They 
established using genetic markers that ASCL1 localises 
distal to Phenylalanine hydroxylase (PAH) and 
proximal to tumor rejection antigen (TRA1) on 
chromosome 12q22-q23 cytogenic interval. (Beatrice 
Renault et al. Genomics 30, 81-83 (1995)). 
LINEAGE: Eukaryota, Metazoa, Chordata, Craniata, 
Vertebrata, Euteleostomi, Mammalia, Eutheria, 
Euarchontoglires, Primates, Haplorrhini, Catarrhini, 
Hominidae, Homo. NCBI GI#: g119618109; 
g22658430; g20455478; g13111927; g12803079; 
g55743094; g306460; g13325212. 
DNA/RNA 
Description 
2 exons spanning 2824bp although only exon1 codes 
for the protein. Orientation '+' strand. Exon 1 
101875594-101876910 (1317 bp), Exon 2 101877270-
101878417 (1148 bp), Intron 1-2 101876911-
101877269 (359 bp). Gene id= 429 (KEGG). Refseq: 
NM_004316.2. 
HASH1/ASCL1 promoter has two independent 
transcription start sites of which proximal INR elem nt 
(YYANYY consensus binding site) plays a 
predominant role. The general enhancer has several 
Sp1 binding sites. Tissue restricted expression control 
comes from the repressor regions present in the distal  
(over 13.5kb upstream) and proximal 5' flanking 
region. The proximal repressor is shown to have a class 
C element site to which HES1 can bind and regulate 
HASH1/ASCL1 expression. 
Variant: 158--158 Glu to Gly (E to G) Var_013179 in 
P50553. 
Transcription 
2.46 Kb mRNA, coding sequence 711 bp. 
Protein 
Note: This gene encodes a member of the basic helix-
loop-helix (bHLH) family of transcription factors. The 
protein activates transcription by binding to the E box 
(5'-CANNTG-3'). Dimerization with other bHLH 
proteins is required for efficient DNA binding. This 
protein plays a role in the neuronal commitment and
differentiation and in the generation of olfactory and 
autonomic neurons. It is highly expressed in medullary 
thyroid cancer (MTC) and small cell lung cancer 
(SCLC) and may be a useful marker for these cancers. 
The proximal coding region of the cDNA contains a 
striking 14-copy repeat of the triplet CAG that exhibits 
polymorphism in human genomic DNA The presence 
of a CAG repeat in the gene suggests that it could play 
a role in tumor formation. 
Protein size: 237 aa, 25.45kDa. Refseq: NP_004307.2. 
Description 
The amino terminal of the protein contains poly alanine 
and poly glutamine repeat rich region. The 
polyglutamine length polymorphism in ASCL1 has 
been postulated that it could influence predispositions 
to Parkinson's disease. The carboxy terminus of the 
protein contains the basic helix loop helix domain, 
which is important for interaction with other 
transcription factors. 
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A: Schematic representation of the ASCL1 genomic DNA depicting exons, introns, transcript and mRNA with untranslated and coding 
region. B: Schematic diagram showing HASH1/ASCL1 promoter with proximal and distal repressors, HASH1/ASCL1 class C site, 
enhancer Sp1 binding sites and transcription initiation sites (TATA box and INR (initiator) element). 
Expression 
The gene product is expressed basically nuclear and is 
expressed in tissues like brain, lung and nervous 
system. 
Function 
ASCL1 functions as a bHLH transcription factor that 
binds to E-box whose canonical sequence is 
5'CANNTG 3'. It also acts as protein binding, 
transcription factor, and in cell differentiation. 
MASH1/ASCL1 is expressed during development of 
rat retina and interacts specifically with an E-box 
identified in the promoter for the opsin gene during rod 
photoreceptor differentiation. NOTCH1 and its 
downstream signal transducer HES1 regulates the 
transcription of HASH1/ASCL1 and is very 
instrumental in neuronal developmental pathways 
particularly dictating neuroendocrine differentiation in 
various organs. 
Interacting partners: E1A binding protein p300, 
Ubiquilin 1, Bone morphogenetic protein 2 (BMP2), 
Trancription factor 3 (TF3), Transcription factor 4 
(TF4), Myocyte specific Enhancer factor 2A 
(MSEF2A), Neurogenin. 
Homology 
Mus musculus Ascl1 achaete-scute complex homolog-
like 1 (Drosophila) NM_008553.2; Rattus norvegicus 
Ascl1 achaete-scute complex homolog-like 1 
(Drosophila) NM_022384.1; Canis familiaris similar to 
achaete-scute homolog 1 LOC482628; Danio Rerio 
achaete scute homolog A asha NM_131219.1. 
Mutations 
Note: Congenital central hypoventilation syndrome is a 
rare disorder of the chemical control of breathing. The 
ASCL1--PHOX2A--PHOX2B developmental cascade 
was proposed as a candidate pathway for this disorder, 
as well as for Haddad syndrome, because the cascade 
controls the development of neurons with a definitive 
or transient noradrenergic phenotype. De Pontual et . 
identified heterozygosity for mutations in the ASCL1 
gene in 2 patients with CCHS and 1 patient with 
Haddad syndrome. The authors also developed an in 
vitro model of noradrenergic differentiation in neuronal 
progenitors derived from the mouse vagal neural crest. 
All Ascl1 mutant alleles result in impaired 
noradrenergic neuronal development when over 
expressed from adenoviral constructs. 
 
 
Schematic representation of ASCL1 protein depicting various motifs such as poly alanine and poly glutamine repeats, a basic motif and 
a bHLH DNA binding motif. 
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ALLELIC VARIANTS  
1. ASCL1 C52A, PRO18THR  
In a patient with CCHS, de Pontual et al identified 
heterozygosity for a 52C-A transversion in the ASCL1 
gene, translating in a pro18-to-thr substitution. The 
patient was also heterozygous for a polyalanine 
expansion mutation in PHOX2B, which is known to 
induce CCHS. 
2. ASCL1, 15-BP DEL, NT111  
Heterozygosity for a 15-bp deletin (111-115 Del 15nt) 
in the ASCL1 gene was reported in a patient with 
CCHS by de Pontual et al. The mutation was predicte 
to result in loss of 5 of 13 alanine residues (ala37-
ala41) in a polyalanine tract. 
3. ASCL1, 24-BP DEL, NT108  
Another heterozygosity for of 24-bp deletion (108-
131del24nt) in the ASCL1 gene was identified in a 
patient with Haddad syndrome (209880), de Pontual et 
al The mutation was predicted to result in loss of 8 of 
13 alanine residues (ala36-ala43) in a polyalanine tract. 
Genetic association with Parkinson's disease has been
shown by Ide M et al (PMID=16021468) and that with 
sudden infant death syndrome or (SIDS) has been 
shown by Weese-Mayer DE et al (PMID= 15240857). 
Implicated in 
Note: Upon characterization of expression of ASCL1 
in several human cancer cell lines and tumors it is 
found that ASCL1 is highly expressed in and has been 
implicated to impart neuroendocrine behaviour to 
various NE- tumors e.g gastrointestinal NE carcinoma 
(NEC), Pheochromocytomas, olfactory neuroblastomas 
or esthesioneuroblastoma, pulmonary and thyroid 
carcinoids, Medullary thyroid cancer (MTC), small cell 
lung cell cancer (SCLC) and recently in prostate small 
cell carcinoma. Apart from this, ASCL1 protein is al o 
shown to be highly upregulated in progressive 
secondary glioblastoma (GBM). Notch signalling down 
regulates ASCL1 levels but its expression is shown to 
be very minimal or non-existent in neuroendocrine 
tumors and hence inhibition of ASCL1 expression that
has been implicated to impart neuroendocrine 
behaviour could be a therapeutic target to suppress 
tumor growth. 
Neuroendocrine tumors 
Note: Neuroendocrine tumors originate from cells that 
are capable of amine precursor (such as dopa and 5-
hydroxytryptophan) uptake and decarboxylation 
(APUD cells). As a result, these tumors have high 
intracellular levels of carboxyl groups and nonspecific 
esterase, which are used as a neuroendocrine marker. 
These tumors have NE- phenotype characterized by 
expression of ACTH, vasopressin, calcitonin gene 
related peptide (CALCA/CGRP), Gastrin releasing 
peptide and secretory proteins like synaptophysin and 
chromogranins, serotonin. HASH1/ASCL1 appears to 
be cardinal/ hallmark feature of each of these tumor 
types. Clinically Chromogranin A is most commonly 
used as a marker to identify NE- tumors. 
Olfactory neuroblastomas or 
Esthesioneuroblastoma (ENB) 
Note: paranasal sinus nasal cavity 
esthesioneuroblastoma or esthesioneurocytoma, 
esthesioneuroma, and esthesioneuroepithelioma. 
Disease 
Esthesioneuroblastoma (ENB) is a rare tumor arising 
out of the nasal vault from cells of the developing 
sympathetic nervous system. When neuroblastoma cells 
are induced to differentiate, as indicated by neuronal 
morphology and upregulation of neuronal marker 
genes, the HASH-1/ASCL1 expression is rapidly 
downregulated with a concomitant, transient 
upregulation of HES-1. ENB is generally a slow-
growing tumor with a high 5-year survival (81%). 
Recurrences usually occur within the first 2 years. 
However, late recurrences are common, and hence 
follow-up must be done for a prolonged time. 
Prognosis 
HASH1/ASCL1 is expressed in immature olfactory 
neurons and is critical for their development. Mhawech 
et al found distinct expression of HASH1/ASCL1 in all 
estersioneuroblastoma samples as compared to the 
poorly differentiated tumors that were negative. They 
also report inverse correlation between grades of 
esthesioneuroblastoma and HASH1/ASCL1 mRNA 
levels and propose that HASH1/ASCL1 could be used 
as useful tool to distinguish estersioneuroblastoma from 
poorly differentiated tumors of sinonasal region. 
Pulmonary and thyroid carcinoids 
Note: Carcinoid tumors or carcinoids. 
Disease 
These tumors originate in hormone-producing cells of 
the gastrointestinal (GI) tract (i.e., esophagus, stomach, 
small intestine, colon), the respiratory tract (i.e., lungs, 
trachea, bronchi), the hepatobiliary system (i.e., 
pancreas, gallbladder, liver), and the reproductive 
glands (i.e., testes, ovaries). Carcinoids are classified as 
slow growing neuroendocrine tumors. They develop in 
peptide- and amine-producing cells, which release 
hormones like serotonin in response to signals from the 
nervous system. Excessive amounts of these hormones 
cause a condition called carcinoid syndrome in 
approximately 10% of patients with carcinoid tumors. 
Prognosis 
Multiple endocrine neoplasia type 1 (MEN1) is a 
genetic disorder that increases the risk for 
neuroendocrine tumors, including carcinoids. 
Gastrointestinal conditions (e.g., peptic ulcer disease, 
pernicious anemia, atrophic gastritis, Zollinger-Ellison 
syndrome) increase the risk for carcinoid tumors of the 
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GI tract. Carcinoid patients also have an increased risk 
for Cushing's syndrome. Atypical Carcinoids (fast 
growing and potentially metastatic) express high levels 
of HASH1/ASCL1 (although lower than NECs) and is 
associated with poor prognosis for survival. 
RAF-1 activation is detrimental to tumorigenesis in 
carcinoid cells. Raf1 activation in an estrogen inducible 
system in pancreatic carcinoid cell line (BON) and i  
pulmonary cell lines leads to marked reduction in NE-
markers such as 5-HT, chromogranin A, and 
synaptophysin and HASH1/ASCL1 has been observed. 
Medullary thyroid cancer (MTC) 
Disease 
Medullary thyroid cancer is a neuroendocrine tumor 
derived from the parafollicular calcitonin producing C 
cells of thyroid and accounts for about 3% of thyroid 
cancers. 
Inheritance: About 20% of have an inherited form of 
the disease and familial MTC are transmitted in an 
autosomal dominant fashion involving mutations in the
RET proto-oncogene. So far surgery remains only 
curative treatment modality. 
Prognosis 
The classical tumor marker and the secreted hormone is 
calcitonin which is tightly regulated by Notch 
signalling and HASH1/ASCL1 levels. It has also been 
shown that by activating RAF-1 signalling mediated by 
MEK induction leads to complete suppression of 
ASCL1 and mRNA protein which is frequently 
upregulated in MTC. HASH1/ASCL1 over expression 
is linked to poor prognostic value. 
Small cell lung cancer (SCLC) 
Note: Oat cell carcinoma. 
Disease 
SCLC cells are small and round to fusiform with scant 
cytoplasm.SCLC tumors are poorly differentiated 
neuroendocrine tumors as compared to bronchoid 
carcinoid tumors and is an aggressive and highly 
metastatic tumor, accounting to about 20% death from 
lung cancer. Owing to its NE-phenotype, these tumors 
secrete chromogranin A, GRP and calcitonin in 
addition to over expressed HASH1/ASCL1. 
Genetically c-myc has shown to be over expressed by 
gene amplification and retinoblastoma (Rb) is 
frequently mutated in SCLC. P53 and PTEN also show 
aberrant expression. Loss of chromosome 3 sequences 
appears to occur frequently at the very earliest stages of 
neoplastic transformation. Losses at the short arms of 
chromosome 3 and 17 and the long arm of 5 are seen 
consistently in almost all SCLC patients. Although to 
date, there are no known examples of amplification or 





HASH1/ASCL1 is associated with significantly 
reduced survival in small cell lung carcinoma patients 
and has adverse prognostic association. 
Pheochromocytomas 
Note: Chromaffin tumors. 
Disease 
Because pheochromocytomas arise from chromaffin 
cells, they are occasionally called chromaffin tumors. 
Pheochromocytomas are found in the adrenal medulla. 
The adrenal medulla normally secretes two hormones, 
called norepinephrine and epinephrine(also known as 
adrenaline). Pheochromocytomas cause the adrenal 
medulla to secrete too much adrenaline and often 
causes the adrenal glands to make excess of hormones 
called catechol-amines which in turn causes high blood 
pressure and other symptoms. 
Atleast in rat pheochromocytoma cell line PC12, 
MASH1/ASCL1 is readily detected which can be 
further induced by NGF treatment. Whether 
HASH1/ASCL1 also is over expressed in human 
cancers needs careful examination and distinction 
between tumor types. 
Inheritance: About 10-25% of this cancer can be 
familial and mutations in genes e.g. VHL, RET, NF1, 
SDHB and SDHD are implicated. 
Prognosis 
Pheochromocytoma can be potentially fatal, but it is 
relatively uncommon (2-8 cases per million people 
annually). As with other neuroendocrine tumors, high 
levels of HASH1/ASCL1 expression seen in 
pheochromocytomas correlate with poor prognosis. 
Activation of MEK1 / MEK2 - ERK1 / ERK2 is 
necessary for differentiation of pheochromocytoma 
(PC12) cells and leads to decreased cell proliferaton. 
Cytogenetics 
Allelic losses at Chromosome 1p, 3p, 17p and 22q have 





Gastrointestinal NECs are defined as small cell 
carcinoma, morphologically similar to the small cell 
carcinoma of the lung. Gastrointestinal NE carcinoma 
(NEC) are extremely aggressive, but its 
pathophysiologic features remain poorly understood. 
Shida et al assessed HASH1/ASCL1 expression in 
human NECs by quantitative RT-PCR and in situ 
hybridisation and showed marked upregulation of 
HASH1/ASCL1 mRNA in NECs which was weak in  
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carcinoid tumors and scarcely expressed in 
adenocarcinomas and normal mucosa. 
Prognosis 
Levels of HASH1/ASCL1 can be used as a more 
sensitive and specific marker than conventional pan-
endocrine markers for clinical diagnosis of 
gastrointestinal tumors to differentiate among 
gastrointestinal tumors particularly between carcinoids, 
adenocarcinomas and neuroendocrine gastrointestinal 
tumors in addition to other NE markers. 




Astrocytoma is the most common type of brain cancer 
arising from the astrocytes affecting cerebral 
hemispheres in adults and the brain stem in children 
accounting to almost 60% of brain tumors. 
According to the world health organization, 
astrocytomas are classified in to four grades: 
1. Grade I or pilocytic astrocytoma (PA); 
2. Grade II diffused astrocytoma (DA); 
3. Grade III Anaplastic astrocyoma (AA); 
4. Grade IV Glioblastoma multiforme (GBM). 
GBM can further be classified as being primary or 
secondary based on the genetic mutations, age at 
occurrence, tendency of progression and clinical 
course. Familial clustering of gliomas is frequently 
observed associated with defined inherited tumor 
syndrome incuding the Li-Fraumeni syndrome, Turcot 
syndrome, and the NF1 syndrome. Several genes have 
been associated in distinguishing one or the other form
of GBM notably among which are P53, MDM2, EGFR, 
CDK4. LOH on chromosome 9,10, 13, 17,19, 22 
frequently occur in GBMs. 
Prognosis 
The median survival time for a GBM individual is 
about 12 months and age at the time of occurrence 
plays a significant prognostic factor. Recently reported 
methylation at the O6- methyl guanine DNA methyl-
transferase (MGMT) promoter has been shown to 
confer favourable prognostic value in terms of response 
to chemotherapy and longer survival. ASCL1 is highly 
upregulated in secondary GBMs as compared to the 
primary GBMs and can be thus ascribed as a 
distinguishing marker between the two. Concomitantly, 
there is repression of NOTCH1 signalling and HES1 
expression in the secondary GBM. It is observed that 
primary GBM patients show rapid tumor progression 
and poor prognosis. 
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